交易 Omeros Corp - OMER 差价合约
Omeros Corp. (NASDAQ: OMER) is a clinical-stage biopharmaceutical company focused on immunologic and complement-mediated diseases. Its pipeline includes OMS906 for PNH and other complement-related disorders, with potential for orphan designation. Omeros offers investors high-risk, high-reward exposure to breakthrough therapies in underserved rare disease markets.最新股票文章

SpaceX上市首日收涨19%——IPO后如何交易SpaceX SPCX差价合约
SpaceX(SPCX)于2026年6月12日在纳斯达克首次上市,开盘报150美元,收盘报160.95美元,较135美元的IPO发行价上涨19.2%。
08:41, 16 六月 2026


